The world’s largest group of clinical endocrinologists, in 13 clinics across 9 cities, within 3 Canadian provinces. Each site is a regional centre of excellence providing multidisciplinary diabetes care for people with Type 1 and Type 2 diabetes, within the Canadian public health system.
All sites use a common electronic medical record system, aligned to Diabetes Canada Clinical Practice Guidelines. All providers follow a consistent and structured approach to diabetes care, based on the clinical practice guidelines.
LMC Diabetes Registry
The LMC Diabetes Registry houses all the medical and demographic information of the cohort under care, including medications, lab results, hypoglycemia, device usage, and glucose monitoring data (Glooko/Clarity/LibreView/Carelink).
Clinical trials are performed in a step-by-step process to ensure that each participant receives careful medical attention from beginning to end. Furthermore, registry data analysis occurs only through patient consent (current consent participation rate is ~92%).
Publications and Impact
The LMC Diabetes Registry has provided foundational insights into the impact of new therapies, educational interventions and devices in the glycemia and outcomes of a large Canadian population with diabetes. Over the past decade, more than 50 major publications and presentations have resulted from analyses of the Registry.
Future directions will include insights into the lower limb health of healthy individuals with diabetes, the prevalence and natural history of non-alcoholic fatty liver disease among the type 2 diabetes population, and the course of diabetic kidney disease in Canadians living with diabetes.
ALL ACTIVE PATIENTS
Type 1 Diabetes (n=4,702)
Type 2 Diabetes (n=41,620)
Chronic Kidney Disease in Type 1 Diabetes
Chronic Kidney Disease in Type 2 Diabetes
- eGFR ≤60 11% 11%
- uACR ≥2.0 25% 25%
- Both eGFR ≤60 and uACR ≥2.0 7% 7%
- Either eGFR ≤60 OR uACR ≥2.0 29% 29%
- eGFR ≤60 27% 27%
- uACR ≥2.0 46% 46%
- Both eGFR ≤60 and uACR ≥2.0 18% 18%
- Either eGFR ≤60 OR uACR ≥2.0 55% 55%